Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which is the most common phase-2 reaction in drug metabolism?

Glucuronide conjugation. Drug metabolism (biotransformation) typically occurs in two phases. Phase-1 (Non-synthetic) involves oxidation, reduction, and hydrolysis, while Phase-2 (Synthetic) involves conjugation reactions to make the drug more water-soluble for excretion [4]. **1. Why Glucuronide Conjugation is Correct:** Glucuronidation is the **most common and most important** Phase-2 reaction [2]. It is mediated by the enzyme **UDP-glucuronosyltransferase (UGT)**. Its dominance is due to the high availability of the substrate (glucuronic acid, derived from glucose) and the wide variety of functional groups (hydroxyl, carboxyl, amino) it can bind to [3]. Most drugs, including morphine, paracetamol, and lorazepam, undergo this process. **2. Analysis of Incorrect Options:** * **Acetylation (B):** Common for drugs like Isoniazid, Hydralazine, and Procainamide (remembered by the mnemonic **SHIP**). It is clinically significant due to genetic polymorphism (fast vs. slow acetylators) but is not the most frequent reaction. * **Methylation (C):** A relatively minor pathway involving enzymes like COMT (for catecholamines) or TPMT (for thiopurines). * **Sulfate Conjugation (D):** Important for steroids and phenolic compounds, but the body has a limited pool of sulfate, making it less common than glucuronidation [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Exception to the Rule:** Most Phase-2 reactions result in inactivation, but **Morphine-6-glucuronide** is a potent active metabolite. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase-2 reaction carried out by microsomal enzymes; all other Phase-2 reactions are non-microsomal (cytosolic). * **Neonatal Physiology:** Newborns are deficient in glucuronyltransferase, leading to "Gray Baby Syndrome" when given Chloramphenicol.

Q: Atrial Natriuretic Peptide receptors belong to which of the following types of receptors?

Ligand-gated guanylyl cyclase receptor. **Explanation:** **Atrial Natriuretic Peptide (ANP)** and Brain Natriuretic Peptide (BNP) exert their physiological effects by binding to **Natriuretic Peptide Receptor-A (NPR-A)**. This receptor is a classic example of a **transmembrane (membrane-bound) Guanylyl Cyclase**. When ANP binds to the extracellular domain, it directly activates the intracellular catalytic domain of the receptor, which converts GTP into **cyclic GMP (cGMP)**. cGMP then activates Protein Kinase G (PKG), leading to vasodilation and natriuresis. This is distinct from soluble guanylyl cyclase, which is activated by Nitric Oxide. **Analysis of Incorrect Options:** * **A. G-protein coupled receptors (GPCRs):** These utilize secondary messengers like cAMP or $IP_3/DAG$. While many hormones use GPCRs, ANP does not. * **C. Tyrosine kinase receptors:** These (e.g., Insulin, EGF) involve autophosphorylation of tyrosine residues. ANP receptors lack tyrosine kinase activity. * **D. JAK-STAT receptors:** These are used by cytokines and Growth Hormone. They do not have intrinsic enzymatic activity but recruit cytosolic Janus Kinases (JAKs). **High-Yield Clinical Pearls for NEET-PG:** 1. **Dual Role:** ANP receptors are both the receptor and the enzyme (Guanylyl Cyclase). 2. **Sacubitril:** A Neprilysin inhibitor used in Heart Failure (ARNI) that prevents the degradation of ANP/BNP, thereby increasing cGMP levels. 3. **Nesiritide:** A recombinant form of BNP used in acute decompensated heart failure, acting via this same cGMP pathway. 4. **Other cGMP-linked drugs:** Sildenafil (PDE-5 inhibitor) prevents the breakdown of the cGMP generated by these pathways.

Q: Which of the following statements regarding drug action is true?

Clinical efficacy is more important than potency.. ### Explanation **1. Why Option A is Correct:** In clinical practice, **efficacy** is the most important parameter of drug action. Efficacy (or maximal efficacy) refers to the maximum therapeutic effect a drug can produce, regardless of the dose. For example, if Patient X has severe pain, a drug with high efficacy (like Morphine) will provide relief, whereas a drug with low efficacy (like Aspirin) may never reach that level of pain control, no matter how much the dose is increased. **Potency**, on the other hand, refers to the amount of drug (dose) required to produce a specific intensity of effect. A "more potent" drug simply requires a smaller dose (e.g., 5mg vs. 500mg) to achieve the same result. Since we can easily adjust the dose or tablet size, potency is rarely a limiting factor in treatment, making efficacy the clinically superior metric. **2. Why Other Options are Incorrect:** * **Option B:** Potency is primarily of academic interest and helps in determining the dose for a prescription. It does not dictate the ultimate therapeutic success. A highly potent drug that lacks efficacy is useless for severe pathology. * **Option C:** While both are pharmacological properties, they are not "equally" important in a clinical setting. Efficacy determines the "ceiling effect" of treatment, which is the primary concern for a physician. **3. NEET-PG High-Yield Pearls:** * **Dose-Response Curve (DRC):** On a graph, **Potency** is represented by the position of the curve along the **X-axis** (left = more potent), while **Efficacy** is represented by the height on the **Y-axis**. * **Clinical Rule:** A drug that is more efficacious is often preferred over one that is merely more potent. * **ED50:** The dose that produces a response in 50% of individuals is used to measure potency.

Q: A drug has a bioavailability of 80% and a volume of distribution of 10 L. Calculate the loading dose required to achieve a plasma concentration of 0.6 mg/L.

7.5 mg. ### Explanation **1. Understanding the Correct Answer (C: 7.5 mg)** The **Loading Dose (LD)** is the initial dose given to rapidly achieve the desired steady-state plasma concentration ($C_p$). The fundamental formula for calculating the loading dose is: $$LD = \frac{V_d \times C_p}{F}$$ * **$V_d$ (Volume of Distribution):** 10 L * **$C_p$ (Target Plasma Concentration):** 0.6 mg/L * **$F$ (Bioavailability):** 80% or 0.8 (This must be accounted for if the drug is not given intravenously). **Calculation:** $$LD = \frac{10 \text{ L} \times 0.6 \text{ mg/L}}{0.8}$$ $$LD = \frac{6 \text{ mg}}{0.8} = 7.5 \text{ mg}$$ **2. Why Incorrect Options are Wrong** * **Option B (0.48 mg) & D (48 mg):** These result from mathematical errors or misplacing decimal points. 48 mg is the result of multiplying all numbers ($10 \times 0.6 \times 8$) without considering the division by bioavailability. * **Option A (0.75 mg):** This is a decimal error. While the digits are correct, the magnitude is off by a factor of 10. **3. NEET-PG Clinical Pearls & High-Yield Facts** * **Loading Dose vs. Maintenance Dose:** Remember that **Loading Dose** depends primarily on the **Volume of Distribution ($V_d$)**, whereas the **Maintenance Dose** depends on **Clearance ($CL$)**. * **Bioavailability ($F$):** For IV administration, $F = 1$. If the question does not specify the route but provides $F$, always include it in the denominator. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration. A loading dose bypasses this delay, which is critical in emergencies (e.g., Lidocaine for arrhythmias or Digoxin for heart failure). * **Vd Concept:** A high $V_d$ (> 42L) suggests the drug is sequestered in tissues (lipophilic), while a low $V_d$ suggests the drug remains in the plasma (large molecules or highly protein-bound).

Q: Which of the following receptors acts the slowest?

Mineralocorticoid receptor. **Explanation:** The speed of a receptor's response is determined by its **mechanism of signal transduction**. Receptors are categorized into four types based on their latency (time to effect): 1. **Mineralocorticoid Receptor (Correct):** This is a **Type 4 (Nuclear/Intracellular) receptor**. These receptors act as ligand-regulated transcription factors. When a hormone (like Aldosterone) binds, the receptor-ligand complex translocates to the nucleus to alter gene expression and protein synthesis. Because this involves transcription and translation, the response takes **hours to days**, making it the slowest class of receptors. **Why the other options are incorrect:** * **Beta 1 and M2 Receptors (Options A & B):** These are **Type 2 (G-Protein Coupled Receptors - GPCRs)**. They work via second messengers (cAMP, IP3/DAG). Their response time is in **seconds**, which is significantly faster than nuclear receptors but slower than ion channels. * **Tyrosine Kinase Receptor (Option C):** This is a **Type 3 (Enzyme-linked) receptor** (e.g., Insulin receptor). These involve a phosphorylation cascade and typically act within **minutes to hours**. **High-Yield NEET-PG Pearls:** * **Fastest Receptors:** Type 1 (Inotropic/Ligand-gated ion channels) like Nicotinic (Nm/Nn) or GABA-A receptors. They act in **milliseconds**. * **Slowest Receptors:** Type 4 (Nuclear). Examples include Steroids (Glucocorticoids, Mineralocorticoids), Thyroid hormones (T3/T4), Vitamin D, and Retinoic acid. * **Memory Aid:** The further the signal has to travel (from membrane → cytoplasm → nucleus → DNA → Protein), the slower the response.

Q: Which route of administration provides 100% bioavailability?

Intravenous. **Explanation:** **1. Why Intravenous (IV) is Correct:** Bioavailability ($F$) is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is administered **Intravenously**, it bypasses all absorption barriers and the "first-pass metabolism" in the liver. The entire dose enters the bloodstream immediately; therefore, by definition, the bioavailability of the IV route is **100% ($F = 1.0$)**. This makes it the gold standard for emergencies where a rapid onset of action is required. **2. Why Other Options are Incorrect:** * **Oral:** This route typically has the lowest and most variable bioavailability due to incomplete absorption from the GI tract and significant **First-Pass Metabolism** (pre-systemic elimination) in the gut wall and liver. * **Rectal:** While it partially bypasses the liver (the lower rectum drains into the systemic circulation via inferior vena cava), absorption is often erratic and incomplete, leading to <100% bioavailability. * **Subcutaneous:** Drugs must diffuse through connective tissue and capillaries to reach the circulation. While usually higher than oral, it is still <100% due to local degradation or slow absorption. **3. NEET-PG High-Yield Pearls:** * **Definition:** Bioavailability is calculated by comparing the **Area Under the Curve (AUC)** of a specific route to the AUC of the IV route: $F = \frac{AUC_{oral}}{AUC_{IV}} \times 100$. * **First-Pass Effect:** Major sites are the **Liver** (most common) and **Gut** (e.g., Tyramine, Midazolam). * **Exceptions:** Some oral drugs like **Warfarin, Diazepam, and Digoxin** have nearly 100% bioavailability despite being given orally. * **Clinical Note:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Lignocaine) cannot be given orally and require sublingual or IV routes.

Q: A 70 kg man was given a drug in a dose of 100 mg/kg body weight. Its half-life is 10 hours, and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Elimination rate constant (k) is 0.0693 hr -1. ### Explanation **1. Why Option C is Correct** The question provides the **half-life ($t_{1/2}$)** of the drug as 10 hours. In pharmacokinetics, the elimination rate constant ($k$) represents the fraction of a drug removed per unit of time [1]. The relationship between half-life and the elimination rate constant is defined by the formula: $k = \frac{0.693}{t_{1/2}}$ Plugging in the values: $k = \frac{0.693}{10 \text{ hours}} = 0.0693 \text{ hr}^{-1}$ This indicates that approximately 6.93% of the drug is eliminated every hour. **2. Why Other Options are Incorrect** * **Option D:** This is a decimal point error ($6.93$ vs $0.0693$). Such distractors are common in NEET-PG to test calculation accuracy. * **Options A & B (Clearance):** To calculate Clearance ($CL$), we first need the Volume of Distribution ($V_d$). * Total Dose = $100 \text{ mg/kg} \times 70 \text{ kg} = 7000 \text{ mg}$. * $V_d = \frac{\text{Dose}}{\text{Plasma Concentration}} = \frac{7000 \text{ mg}}{1.9 \text{ mg/ml}} \approx 3684 \text{ ml}$ or $3.68 \text{ L}$. * $CL = k \times V_d = 0.0693 \times 3.68 \approx 0.25 \text{ L/hr}$. Neither 0.02 nor 0.2 L/hr is the precise value, making these options mathematically incorrect. **3. Clinical Pearls & High-Yield Facts** * **First-Order Kinetics:** Most drugs follow first-order kinetics, where a **constant fraction** of the drug is eliminated per unit time ($k$ is constant) [1]. * **Zero-Order Kinetics:** A **constant amount** of drug is eliminated (e.g., Phenytoin, Alcohol, Salicylates at high doses) [1]. Here, $t_{1/2}$ is not constant. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body. * **Formula Recap:** $CL = V_d \times k$ and $t_{1/2} = \frac{0.693 \times V_d}{CL}$.

Q: A loading dose of 25 mg was administered to achieve a plasma concentration of 0.5 mg/L. If the volume of distribution is 40 L, what is the bioavailability?

80%. ### Explanation **1. Understanding the Correct Answer (C: 80%)** The core concept here is the relationship between **Loading Dose (LD)**, **Volume of Distribution (Vd)**, **Target Plasma Concentration (Cp)**, and **Bioavailability (F)**. The standard formula for Loading Dose is: $$LD = \frac{Cp \times Vd}{F}$$ To find the Bioavailability (F), we rearrange the formula: $$F = \frac{Cp \times Vd}{LD}$$ **Calculation:** * Target Concentration (Cp) = 0.5 mg/L * Volume of Distribution (Vd) = 40 L * Administered Dose (LD) = 25 mg $$F = \frac{0.5 \text{ mg/L} \times 40 \text{ L}}{25 \text{ mg}}$$ $$F = \frac{20 \text{ mg}}{25 \text{ mg}} = 0.8$$ To express this as a percentage: $0.8 \times 100 = \mathbf{80\%}$. **2. Why Other Options are Incorrect** * **A (40%), B (50%), and D (70%):** These values do not satisfy the pharmacokinetic equation. If the bioavailability were 40% or 50%, the achieved plasma concentration would be significantly lower than 0.5 mg/L for the same dose, as more of the drug would be "lost" before reaching systemic circulation. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **Loading Dose:** It is used to achieve the **Steady State Concentration (Css)** rapidly. It depends primarily on the **Volume of Distribution** and is independent of the drug's half-life ($t_{1/2}$). * **Maintenance Dose:** This is used to maintain the Css and depends primarily on the **Clearance (CL)** of the drug. * **Bioavailability (F):** For intravenous (IV) administration, $F = 1$ (or 100%). For any other route (oral, IM, etc.), $F$ is usually $< 1$ due to incomplete absorption or first-pass metabolism. * **Vd Concept:** A drug with a high Vd (e.g., Digoxin, Chloroquine) is sequestered in tissues and requires a higher loading dose to achieve target plasma levels.

Q: Which of the following receptors is coupled to a heterotrimeric G protein?

GABA-B receptor. **Explanation:** The core concept tested here is the classification of receptors into **Ionotropic** (ligand-gated ion channels) and **Metabotropic** (G-protein coupled receptors or GPCRs). **Why GABA-B is correct:** The **GABA-B receptor** is a metabotropic receptor coupled to a **heterotrimeric G-protein** (specifically $G_i/G_o$). Activation of GABA-B leads to the inhibition of adenylyl cyclase, opening of potassium ($K^+$) channels (causing hyperpolarization), and closing of calcium ($Ca^{2+}$) channels. This mediates slow, prolonged inhibitory postsynaptic potentials. **Why the other options are incorrect:** * **Glycine receptor (Option A):** This is an **ionotropic** receptor. It is a pentameric chloride ($Cl^-$) channel that mediates fast inhibition in the spinal cord and brainstem. * **Nicotinic ACh receptor (Option C):** The Nm receptor at the neuromuscular junction is a classic **ionotropic** receptor. It is a ligand-gated cation channel ($Na^+/K^+$) that mediates rapid skeletal muscle contraction. * **5-HT3 receptor (Option D):** This is the **only ionotropic serotonin receptor**. All other serotonin receptors (5-HT1, 2, 4–7) are GPCRs. 5-HT3 is a non-selective cation channel involved in the emetic reflex. **High-Yield Clinical Pearls for NEET-PG:** * **GABA-A vs. GABA-B:** Remember "A" for **A**qua/Ion (Ionotropic - $Cl^-$ channel) and "B" for **B**oth/GPCR (Metabotropic). * **Baclofen** is a specific GABA-B agonist used clinically as a centrally acting muscle relaxant for spasticity. * **Fast vs. Slow:** Ionotropic receptors (A, C, D) act in milliseconds, while GPCRs (B) take seconds to minutes. * **Common Ionotropic Receptors (Mnemonic: "GANG"):** **G**ABA-A, **A**MPA/NMDA/Kainate, **N**icotinic, **G**lycine, and 5-HT3.

Question 1

Which is the most common phase-2 reaction in drug metabolism?

Accepted Answer

Glucuronide conjugation

Answer

Acetylation

Answer

Methylation

Answer

Sulfate conjugation

Question 2

Atrial Natriuretic Peptide receptors belong to which of the following types of receptors?

Accepted Answer

Ligand-gated guanylyl cyclase receptor

Answer

G-protein coupled receptors

Answer

Tyrosine kinase receptors

Answer

JAK-STAT receptors

Question 3

Which of the following statements regarding drug action is true?

Accepted Answer

Clinical efficacy is more important than potency.

Answer

Clinical potency is more important than efficacy.

Answer

Both potency and efficacy are equally important clinically.

Answer

None of the above statements are true.

Question 4

Low V4 means:

Accepted Answer

The drug does not accumulate in tissues.

Answer

The drug has a low half-life.

Answer

The drug has low bioavailability.

Answer

The drug has weak plasma protein binding.

Question 5

A drug has a bioavailability of 80% and a volume of distribution of 10 L. Calculate the loading dose required to achieve a plasma concentration of 0.6 mg/L.

Accepted Answer

7.5 mg

Answer

0.75 mg

Answer

0.48 mg

Answer

48 mg

Question 6

Which of the following receptors acts the slowest?

Accepted Answer

Mineralocorticoid receptor

Answer

Beta 1 receptor

Answer

M2 receptor

Answer

Tyrosine kinase receptor

Question 7

Which route of administration provides 100% bioavailability?

Accepted Answer

Intravenous

Answer

Oral

Answer

Rectal

Answer

Subcutaneous

Question 8

A 70 kg man was given a drug in a dose of 100 mg/kg body weight. Its half-life is 10 hours, and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Accepted Answer

Elimination rate constant (k) is 0.0693 hr
-1

Answer

Clearance is 0.02 litre/hr

Answer

Clearance is 0.2 litre/hr

Answer

Elimination rate constant (k) is 6.93 hr
-1

Question 9

A loading dose of 25 mg was administered to achieve a plasma concentration of 0.5 mg/L. If the volume of distribution is 40 L, what is the bioavailability?

Accepted Answer

80%

Answer

40%

Answer

50%

Answer

70%

Question 10

Which of the following receptors is coupled to a heterotrimeric G protein?

Accepted Answer

GABA-B receptor

Answer

Glycine receptor

Answer

Nicotinic acetylcholine receptor at myoneural junction

Answer

5-HT3 receptor

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?